Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors
C Zhou, Z Yuan, W Ma, L Qi, A Mahavongtrakul… - Journal of hematology & …, 2018 - Springer
Background This retrospective study was undertaken to determine if the plasma circulating
tumor DNA (ctDNA) level and tumor biological features in patients with advanced solid …
tumor DNA (ctDNA) level and tumor biological features in patients with advanced solid …
Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study
X Lin, M Peng, Q Chen, M Yuan, R Chen… - Frontiers in …, 2021 - frontiersin.org
Background Epidemiological surveys have suggested that lung cancer has inherited
susceptibility and shows familial aggregation. However, the distribution and prevalence of …
susceptibility and shows familial aggregation. However, the distribution and prevalence of …
A Primary Lung and Breast Cancer Patient with Germline EGFR R776H Mutation: A Case Report and Literature Review
D Li, X Liu, SQ Cui, DF Yang, Y Zhu, E Pan… - OncoTargets and …, 2023 - Taylor & Francis
For advanced non-small cell lung cancer (NSCLC) patients with common epidermal growth
factor receptor (EGFR) mutations (exon 19 deletions or the exon 21 L858R mutation) …
factor receptor (EGFR) mutations (exon 19 deletions or the exon 21 L858R mutation) …
Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC
Background Lack of biomarkers and in vitro models has contributed to inadequate
understanding of the mechanisms underlying the inferior clinical response to immune …
understanding of the mechanisms underlying the inferior clinical response to immune …
[图书][B] Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA for Therapy Response Monitoring and Early Detection of Cancer
JC Nesvet - 2020 - search.proquest.com
In the era of precision medicine, molecular subtyping of non--small cell lung cancer
(NSCLC) has revolutionized therapeutics tailored to individual actionable mutations …
(NSCLC) has revolutionized therapeutics tailored to individual actionable mutations …